Does Cosentyx Cause Eye Problems?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists eye-related side effects in its prescribing information. These include conjunctivitis (pink eye), uveitis (inflammation inside the eye), and less commonly, scleritis or iritis. Clinical trials reported ocular inflammation in 0.4-1.6% of patients, higher than placebo rates.[1][2]
Real-world data from post-marketing surveillance shows these risks persist, with uveitis cases linked to IL-17 blockade disrupting immune regulation in the eye.[3]
How Common Are Eye Side Effects with Cosentyx?
In pivotal trials:
- Conjunctivitis: Up to 1% of patients.
- Uveitis: 0.1-0.5%, sometimes leading to discontinuation.
Adverse event databases like FAERS report hundreds of ocular cases since approval in 2015, though causality isn't always confirmed.[1][4]
Patients with pre-existing inflammatory eye conditions face higher risk, as Cosentyx may exacerbate them.
What Eye Symptoms Should You Watch For?
Report these promptly:
- Redness, pain, or blurred vision.
- Sensitivity to light or floaters (uveitis signs).
- Dry eyes or itching (conjunctivitis).
Severe cases can cause vision loss if untreated; ophthalmologist evaluation is standard for suspected uveitis.[2][5]
Why Does Cosentyx Affect the Eyes?
IL-17 plays a role in protecting against ocular pathogens and regulating inflammation. Blocking it can trigger or worsen uveitis, especially in those with HLA-B27 positivity (linked to spondyloarthropathies).[3][6]
No direct toxicity to eye tissues, but immune modulation shifts balance toward inflammation.
Can Eye Risks Be Managed or Prevented?
Screening includes baseline eye exams for at-risk patients. If issues arise:
- Pause Cosentyx and treat with steroids or immunosuppressants.
- Switch to TNF inhibitors (lower uveitis risk) if recurrent.[5][7]
Monitor every 3-6 months if history of uveitis.
How Does Cosentyx Compare to Other Biologics for Eye Safety?
| Drug | Uveitis Risk | Key Notes |
|------|--------------|-----------|
| Cosentyx (IL-17) | Moderate (0.5%) | Higher new-onset uveitis vs. TNFs. |
| Humira/Enbrel (TNF) | Low (0.1-0.3%) | Often used to treat uveitis. |
| Stelara (IL-12/23) | Low | Fewer ocular reports. |
| Tremfya (IL-23) | Very low | Minimal eye events in trials. [7][8] |
IL-17 inhibitors like Cosentyx and Taltz carry boxed warnings for infections but not specifically eyes; TNFs are preferred for uveitis-prone patients.
Who Is Most at Risk?
- History of uveitis or IBD.
- HLA-B27 positive.
- Long-term use (>1 year).[6]
Consult a doctor before starting; not contraindicated but requires caution.
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: PubMed: IL-17 Inhibitors and Uveitis (Review, 2022)
[4]: FAERS Database via FDA
[5]: American Academy of Ophthalmology: Biologics and Uveitis
[6]: Rheumatology Journal: Ocular Risks of Secukinumab (2021)
[7]: NEJM: Comparative Safety of Biologics in PsA (2020)
[8]: DrugPatentWatch: Secukinumab Patents